Gastric cancer risk in carriers of high-risk Helicobacter pylori variants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort that follows adults with a baseline negative gastric endoscopy and classifies them by H. pylori SNP subtype (high‑risk vs non‑high‑risk). Participants will undergo regular follow‑up examinations to record new cases of gastric cancer and the progression of precancerous lesions such as atrophic gastritis and intestinal metaplasia. The primary comparison is the incidence of gastric cancer between the two genetic-subtype groups over the follow‑up period. Secondary analyses will track cumulative incidence and lesion progression and explore interactions between H. pylori SNP risk status and factors like age, sex, diet, smoking, alcohol use, and family history.

Why it matters

Who can join: the full rules

Inclusion Criteria :

1. Age ≥ 40 years, gender is not limited.
2. Able and willing to provide informed consent and willing to undergo baseline and follow-up examinations.

Exclusion Criteria:

1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.
2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.
3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior.
4. Pregnant or breastfeeding women.
5. Other conditions that the investigator deems inappropriate for participation in the study.

Where it's running

• People's Hospital of Tongling City
  Tongling, China Recruiting

Study contacts

• Study coordinator: Dazhi Xu, PhD
• Email: xudzh@fudan.edu.cn
• Phone: 86-18121299796

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Keverprazan-Minocycline Dual Therapy vs Bismuth Quadruple Therapy for H. pylori Eradication

  This trial tests whether a keverprazan-minocycline dual therapy can eradicate Helicobacter pylori as well as or better than a bismuth-based quadruple therapy in adults who haven’t had eradication treatment before.

  Recruiting Phase 3 Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07904429

• Prevalence and possible role of non-H. pylori Helicobacter species in gastric conditions and cancers

  Researchers will test stomach tissue from people with functional dyspeasia, various gastritis conditions, gastric cancer, and bariatric patients to see if non-H. pylori Helicobacter species are present.

  Recruiting at 3 sites Universiteit Antwerpen · Edegem and 2 other locations · NCT07770126

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• First-in-human dose study of DA-3501 for CLDN18.2-positive stomach, GEJ cancer, and pancreatic cancer

  A first-in-human study tests DA-3501 in adults with CLDN18.2-positive advanced stomach/GEJ cancer or pancreatic cancer to find a safe, effective dose.

  Recruiting at 3 sites Phase 1 Dong-A ST Co., Ltd. · Seongnam, Bundang and 2 other locations · NCT07481357

• Gastric cancer characteristics and care patterns in Algeria

  This project collects medical records and short interviews to describe who has gastric cancer and how they are diagnosed and treated at Algerian oncology centers.

  Recruiting Société Algérienne de Formation et Recherche en Oncologie · Algiers, Algeria and 14 other locations · NCT07481110

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.